trending Market Intelligence /marketintelligence/en/news-insights/trending/ZkKAxt0qRTTOFizc2h77dQ2 content esgSubNav
In This List

Intra-Cellular to provide more data for US FDA application of schizophrenia drug

Case Study

Identifying PPE Suppliers During the Pandemic


Highlighting the Top Regional Aftermarket Research Brokers by Sector Coverage


COVID-19 Impact & Recovery: Healthcare Outlook for H2 2021


Corporate Credit Risk Trends in Developing Markets: A Loss Given Default (LGD) Perspective

Intra-Cellular to provide more data for US FDA application of schizophrenia drug

Intra-Cellular Therapies Inc. said the U.S. Food and Drug Administration has agreed to let the company submit additional information regarding its new drug application for lumateperone to treat schizophrenia.

The FDA classified the planned submission as a major amendment to the application and extended the review period by three months. The U.S. regulator plans to make a decision on the New York-based pharmaceutical company's application by Dec. 27.

The new information will cover findings from previous animal studies that show species-specific differences in the breakdown of the drug. Additionally, Intra-Cellular will analyze animal and human plasma samples from previous studies to confirm that lumateperone goes through different chemical reactions in different species.

Intra-Cellular's application for lumateperone is based on results from 20 clinical studies. The FDA granted a fast-track designation to the drug for treating patients with schizophrenia in November 2017.

The pharmaceutical company is also developing lumateperone as a therapy for bipolar disorder, behavioral disturbances in patients with Alzheimer's disease, depression, and other neuropsychiatric and neurological disorders.

The shares of Intra-Cellular were up 8.39% to $8.85 at 1:49 p.m. on Aug. 5.